drugset / Trial / NCT04380012
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Phase 2
Unknown
40 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
First Affiliated Hospital of Zhejiang University · collabSir Run Run Shaw Hospital · collabZhejiang Cancer Hospital · collabZhejiang Provincial People's Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To Observe the Efficacy and Safety of Pyrotinib Maleate in Patients With HER2-positive Advanced Colorectal Cancer
Timeline
- Start
- 2019-12-17
- Primary completion
- 2021-12-17
- Completion
- 2022-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |